The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.
Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.
Hosted on MSN3d
Regeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...
Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.
On December 9, REGN announced new and positive data for odronextamab monotherapy in patients with previously untreated follicular lymphoma with twelve abstracts spanning several B-cell non-Hodgkin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback